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SUMMARY
The biggest threat to the war on malaria is the continued evolution of drug resistance by the parasite. Resistance to almost
all currently available antimalarials now exists in Plasmodium falciparum which causes the most suﬀering among all
human malaria parasites. Monitoring of antimalarial eﬃcacy and the development and subsequent spread of resistance
has become an important part in the treatment and control of malaria.With recent reports of reduced eﬃcacy of artemisinin,
the current recommended treatment for uncomplicated malaria, there is urgent need for better methods to recognize
and monitor drug resistance for eﬀective treatment. Molecular markers have become a welcome addition to
complement the more laborious and costly in vitro and in vivo methods that have traditionally been used to monitor
drug resistance. However, there are currently no molecular markers for resistance to some antimalarials. This
review highlights the role of the various genetic and genomic approaches that have been used in identifying the
molecular markers that underlie drug resistance in P. falciparum. These approaches include; candidate genes, genetic
linkage and genome-wide association studies.We discuss the requirements and limitations of each approach and use various
examples to illustrate their contributions in identifying genomic regions of the parasite associated with antimalarial drug
responses.
Key words: Candidate gene, drug resistance, genome-wide association, linkage analysis, malaria, molecular markers,
Plasmodium falciparum.
INTRODUCTION
The malaria parasite Plasmodium falciparum has
developed clinically signiﬁcant resistance to all
classes of antimalarial drugs, with the latest being
reduced sensitivity to artemisinin and its derivatives
(Dondorp et al. 2009). The World Health Organiz-
ation (WHO) deﬁnes drug resistance as the ability of
a parasite strain to multiply or to thrive in the pres-
ence of drug concentrations that normally destroy
parasites of the same species or prevent their
multiplication (World Health Organization, 1973).
Resistance may be relative, with the parasite surviv-
ing increased doses of the drug that can be tolerated
by the host (drug tolerance), or complete, when the
parasites can withstand maximum doses tolerated by
the host (outright resistance). In both cases, higher
drug concentrations are required to achieve the same
levels of parasite clearance (White, 2004).
Resistance emerges de novo through spontaneous
mutations and/or gene duplications, which are
thought to occur independently of drug selection
pressure. In the presence of the drug, the mutated
parasites have a selective advantage and their
frequency in the population increases at a rate
proportional to the selective pressure (drug use)
(Hastings andMackinnon, 1998). The mutations and
gene duplications confer drug resistance through a
number of mechanisms including alterations of
drug transport and permeability, conversion of the
drug to a form with lower activity, increased
expression of the drug target, and alterations to the
drug target that lowers its binding aﬃnity to the
inhibitor (White, 1992). Recently, more evidence has
emerged to show that drug-resistant parasites can
enter a quiescent state in the presence of some drugs,
and later continue with normal cell cycle progression
once the drug concentrations have waned (Codd et al.
2011).
Drug eﬃcacy monitoring and continuous surveil-
lance of any emerging resistance have become
essential facets ofmalaria control strategies for the de-
ployment of eﬀective antimalarial drugs. Informative
molecular markers of resistance are needed to moni-
tor the emergence and spread of drug resistance, as an
alternative to time-consuming and expensive drug
eﬃcacy trials. This review summarizes the evolution
of resistance to antimalarial drugs in P. falciparum,
and the genetic and genomic methods used to map
the markers of this resistance.
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THE EVOLUTION AND SPREAD OF ANTIMALARIAL
DRUG RESISTANCE
Resistance to antimalarial drugs has now been de-
scribed for two of the ﬁve species of malaria parasite
that naturally infect humans, P. falciparum and
P. vivax, and the emergence of resistance usually
reﬂects the extent of use of each antimalarial drug
once it has been introduced.
Quinine is one of the oldest known antimalarials,
ﬁrst documented to have been used as an antimalarial
in 1631 in Rome (Bruce-Chwatt, 1988), although it
was probably used for centuries by natives of Peru
and Bolivia to treat chills and fevers. Quinine is
an aryl-amino alcohol extracted from the bark of
the cinchona tree; chemical isolation was achieved
in 1820, but before that dried and ground bark
were mixed with sweetened water to oﬀset its bitter
taste, forming tonic water (Jarcho and Torti, 1993).
Despite the widespread use of quinine in the
nineteenth century, the ﬁrst documented reports of
drug resistance were not until 1910 (Nocht and
Werner, 1910), and today resistance to quinine is still
low and limited to SE Asia, Oceania and, less fre-
quently, South America (Pickard and Wernsdorfer,
2002). Chemical synthesis of quinine was not ac-
hieved until 1944, but a number of synthetic drugs
based on the structure of quinine were manufactured,
the ﬁrst in 1928, and these form a widely used class of
antimalarials known as the quinoline drugs. Quinine
itself remained in wider use than its synthetic
counterparts until World War II, when the supply
of quinine from countries in the South Paciﬁc was cut
oﬀ by Japanese military conquest.
The ﬁrst fully synthetic 4-aminoquinoline anti-
malarials were produced in the 1930s, two of which –
chloroquine (CQ) (e.g. Avochlor®) and amodiaquine
– are still in use today (Surrey and Hammer, 1946).
CQ was introduced for treatment and control of
malaria in the 1940s and quickly became the drug of
choice for most malaria-endemic countries. The ﬁrst
reports of conﬁrmed P. falciparum resistance to CQ
came from South America (Colombia, Brazil and
Venezuela) in 1960 (Wernsdorfer, 1991). These were
followed very soon afterwards by reports of resistance
in Southeast Asia (Thailand and Kampuchea) in
1961 (Hartinuta et al. 1962). By 1973, chloroquine
resistance (CQR) was widespread in South America
and Asia but there was still no resistance in sub-
Saharan Africa (World Health Organization, 1973).
CQR in Africa was not observed until the late 1970s
when its emergence was ﬁrst seen in the east, in
Kenya and Tanzania (Campbell et al. 1979; Fogh
et al. 1979), from where it spread to the west. By
1989, the distribution of CQR was virtually identical
to that of P. falciparum (Wernsdorfer and Payne,
1991). Another quinine-like drug, meﬂoquine, was
ﬁrst introduced in 1977, but resistance was reported
from the Thai–Myanmar and the Thai–Cambodian
borders in 1982 (Wongsrichanalai et al. 2001),
although the drug remains eﬀective outside of the
SE Asia and some regions of South America.
The antifolate drugs were developed as antibac-
terial agents but were also found to have activity
against malaria parasites (Curd et al. 1945).
Antifolate drugs, such as pyrimethamine, were ﬁrst
used as antimalarials in the late 1940s; resistance to
pyrimethamine was reported very soon after its intro-
duction (Coatney et al. 1952). Drug resistance be-
came most evident during the Global Malaria
Eradication campaign launched by WHO in 1955
(Bruce-Chwatt, 1956). The introduction of salt
medicated with antimalarials (especially pyrimetha-
mine) to increase coverage of larger populations
may have contributed to the emergence of parasites
showing increased tolerance to the drugs. Interven-
tions based on the introduction of pyrimethamine-
medicated salts in Kenya, Ghana, the former Dutch
New Guinea and Cambodia, among others, showed
that, despite an initial reduction, parasite rates re-
turned to pre-intervention levels within a period
of six months (Avery, 1958; World Health Organiz-
ation, 1961; Eyles et al. 1963). While chloroquine-
medicated salts seemed to induce resistance less
easily, the ﬁrst cases of chloroquine-resistant para-
sites originated from or near areas where chloro-
quine-medicated salts had been in use (Payne, 1988).
Combinations of antifolate drugs inhibiting two
enzymes in the folate pathway, dihydrofolate
reductase and dihydropteroate synthase, were intro-
duced in the 1960s to try to overcome resistance to
monotherapy (World Health Organization, 1981).
The ﬁrst combination of antifolates was Maloprim®,
a combination of the sulfone, dapsone, and pyri-
methamine, but clinical trials were not encouraging
and parasite resistance developed rapidly (Peters,
1985). Fixed-dose combinations such as sulfadoxine-
pyrimethamine (SP, Fansidar®) gradually replaced
CQ as ﬁrst-line antimalarials, as CQ resistance in-
creased. Resistance to SP emerged in SE Asia and the
Amazon basin in the mid-1970s (White, 1992) and in
Africa in the 1990s. Resistance to SP developed
rapidly after its introduction, and in both SEAsia and
Africa it was only useful for about six years before
resistance reached unacceptably high levels (White,
2004; Anderson and Roper, 2005).
Atovaquone, a lipophilic hydroxynaphthoqui-
none, was developed in the 1980s and found to have
potent activity against a range of pathogens including
Plasmodium (Hudson et al. 1991). It is structurally
related to ubiquinone (coenzyme Q) which is an
important part of the mitochondrial electron trans-
port chain (Fry and Pudney, 1992). Resistance to
atovaquone develops very rapidly when it is used
alone, but develops more slowly when used in com-
bination with drugs such as proguanil (Malarone®)
(Chiodini et al. 1995; Looareesuwan et al. 1996;
Radloﬀ et al. 1996).
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Resistance to CQ and antifolates was widespread
by 2004, and in 2006 the World Health Organization
recommended the deployment of artemisinin-based
combination therapies (ACTs) as ﬁrst-line treatment
for uncomplicated P. falciparum malaria (World
Health Organization, 2010). Artemisinin (ART) is a
sesquiterpene lactone endoperoxide with potent
antimalarial activity, and was originally isolated
from Artemisia annua, a herb used as an ancient
Chinese herbal remedy (Meshnick et al. 1996). ART
and its derivatives, artesunate, dihydroartemisinin
and artemether, are very fast-acting (which helps to
reduce the parasite load quickly), act against the
broadest range of asexual blood-stage parasites of
all known antimalarials, and they also inhibit de-
velopment of gametocytes (Price et al. 1996).
However, their very short half-life in plasma, about
2 h, means that recrudescence is common when ART
is used as monotherapy. ART and its derivatives are
therefore recommended to be administered with a
partner drug with a longer-lasting half-life. Common
coformulations include artemether–lumefantrine,
artesunate–amodiaquine, artesunate–sulfadoxine/
pyrimethamine and artesunate–meﬂoquine (Olliaro
and Wells, 2009; Wells et al. 2009).
The ﬁrst reports of ACT clinical failure were
made in 2003 near the Thai–Cambodian border
(Vijaykadga et al. 2006) following artesunate-
meﬂoquine treatment, but it was not possible to
establish whether this failure was due to artesunate or
the partner drug, meﬂoquine. Subsequent studies
in western Cambodia veriﬁed artesunate tolerance
characterized by delayed clearance times following
treatment (Noedl et al. 2008). A large study,
conducted in Western Cambodia and northwestern
Thailand, provided the clearest evidence of emerging
ART resistance (Dondorp et al. 2009); following
artesunate monotherapy or artesunate–meﬂoquine
treatment, parasite clearance times were prolonged
from 48 to 72 h and from 54 to 84 h respectively. It
has since been shown that ART resistance is a heri-
table trait (Anderson et al. 2010). In an in vitro study,
Witkowski et al. (2010) showed that parasites selected
for ART resistance survive high doses of the drug by
going into a state of developmental quiescence at the
ring stage. These parasites were able to resume
normal growth following the removal of the drug.
Thus, at the time of writing this review, there is
existing resistance, or reduced eﬃcacy, to all anti-
malarial drugs used for the treatment of P. falcipar-
um. Monitoring the levels of drug resistance present
in the malaria parasites in a region is crucial for
eﬀective control of the disease.
APPROACHES TO INVESTIGATE DRUG
RESISTANCE IN MALARIA
There are three established approaches used to inves-
tigate the genes inmalaria parasites involved inmodu-
lating drug responses: candidate gene approach,
linkage analysis and genome-wide association
analysis (GWAS). We have used various examples
to describe each of these approaches to identify para-
site genes or genomic regions involved in antimalarial
drug resistance, summarized in Table 1.
Discovery of drug resistance markers through
investigation of candidate genes
The candidate gene approach involves the investi-
gation of polymorphism within a target gene, and the
association of speciﬁc alleles with the parasite’s
response to the drug. This does not mean that mu-
tations associated with resistance only occur in target
genes and it is possible that resistance could arise via
mutations in or changes in expressions of non-target
genes such as transporters. The approach relies
almost entirely on having prior knowledge of the
drug’s mode of action, or at least its target pathway.
While it has also been recently used to prioritize of
genes identiﬁed through linkage analysis and GWAS
studies (Van Tyne et al. 2011; Cheeseman et al.
2012), it is the former approach that is addressed
here. The best examples of successful identiﬁcation
of drug resistance markers through the candidate
gene approach are for the parasite genes that modu-
late resistance to the antifolates and to atovaquone
and, to an extent, CQ.
Table 1. Summary of the three diﬀerent approaches to identify markers of drug resistance in malaria
parasites
Approach Prior knowledge or resources required
Examples of drug resistance genes
discovered this way
Candidate gene Mode of action of drug or target of
drug action.
Pyrimethamine (Cowman et al. 1988)
Atovaquone (Korsinczky et al. 2000)
Chloroquine (Foote et al. 1989)
Linkage analysis Genetic cross between parasites with
diﬀerent levels of drug response.
Genetic map (genotyping) of progeny
of the cross.
Chloroquine (Wellems et al. 1991;
Fidock et al. 2000)
Quinine (Ferdig et al. 2004)
Pyrimethamine (Peterson et al. 1988)
GWAS Patient samples with diﬀerent drug responses.
Detailed genotyping of each sample.
Artemisinin (Cheeseman et al. 2012)
Halofantrine (Van Tyne et al. 2011)
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Type II antifolate drugs and dihydrofolate reductase
(dhfr). Antifolate drugs are designed to mimic the
essential metabolites of the malaria parasite in the
folate pathway, and are active against all the growing
stages in the liver, erythrocytic stages and growing
stages in the mosquito (sporogonic stages).
The parasite dhfr gene was implicated in drug
resistance, when it was shown that P. berghei strains
resistant to pyrimethamine had increased levels of the
DHFR protein and decreased binding aﬃnity of the
drug to the enzyme (Diggens et al. 1970). Genetic
crossing experiments in bothP. chabaudi andP. yoelii
using pyrimethamine-sensitive and pyrimethamine-
resistant strains showed that the resistance phenotype
segregated as a single gene in both cases. This gene
was conﬁrmed to be dhfr (Walliker et al. 1975, 1976;
Knowles et al. 1981). In the case of P. chabaudi, no
large diﬀerences in the enzyme amounts or turnover
numbers were observed between resistant and sensi-
tive clones. Later investigations of enzyme kinetics
revealed a large decrease in aﬃnity for binding of
pyrimethamine with the enzyme from a resistant
clone of P. chabaudi, together with changes in kinetic
and other properties, indicating that the resistance is
due to genetic change leading to a structurally diﬀer-
ent enzyme (Sirawaraporn and Yuthavong, 1984).
Pyrimethamine resistance in P. falciparum was
also suggested to be associated with genetic change in
the dhfr gene: the resistant phenotype was inherited
in a genetic cross with a linkage group from the
pyrimethamine-resistant parent containing the di-
hydrofolate reductase- thymidylate synthase (dhfr-ts)
gene, and sequence data revealed a single mutation in
the parents of the genetic cross, conferring an amino
acid change from serine to asparagine at codon 108
of the DHFR domain (Cowman et al. 1988; Peterson
et al. 1988). Subsequently, the same polymorphism
in P. falciparum dhfr was found in a number of
pyrimethamine-resistant and -sensitive clones, both
from the laboratory and the ﬁeld, and additional
mutations in codons 51 and 59 were suggested to
underlie increased resistance to the drug (Cowman
et al. 1988; Peterson et al. 1988, 1991). It is now well
established that high-level pyrimethamine resistance
results from the accumulation of mutations in the
dhfr gene, principally at codons 108, 59 and 51, giv-
ing rise to S108N, C59R and N51I. The mutations
appear sequentially in pyrimethamine-treated popu-
lations, with the S108N mutation appearing ﬁrst,
followed by N51I or C59R (Plowe et al. 1997).
However, only the S108N mutation has been found
to occur singly in nature leading to suggestions that
mutations either or both at codons 51 and 59 act pre-
dominantly by restoring the enzymatic defects that
occur as a consequence of the original point mutation
at position 108 (Hastings, 2004). Parasites with ad-
ditional mutations of isoleucine to leucine at codon
164 (I164L) have increased levels of resistance to
pyrimethamine (Cowman et al. 1988; Foote et al.
1990a; Basco et al. 1996). The various dhfrmutations
and the associated inhibitory concentrations as
measured in vitro are summarized in Fig. 1.
Variation at residue 16 (Ala-16 to Val A16 V) confers
resistance only to cycloguanil and the variation is
always found to be associated with S108 T variation
(Foote et al. 1990a).
Atovaquone and the cytochrome bc1 complex. Hydroxy-
naphthoquinones have long been known to inhibit
respiration through inhibition of enzymes in the
mitochondrial respiratory chain and were ﬁrst de-
veloped as antimicrobials in the 1940s (Anﬁnsen,
1947; Ball et al. 1947). Atovaquone (2-[trans-4-(4′-
chlorophenyl) cyclohexyl] 3-hydroxy-1,4-naphtho-
quinone), a structural analogue of ubiquinone
(coenzyme Q), was developed as an antimalarial in
Fig. 1. Common variants of P. falciparum DHFR and their levels of pyrimethamine resistance in vitro. The x axis refers
to the position and amino acid within the protein, using single letter coding. IC50 levels are the approximate values for
the concentration of pyrimethamine (μM) required to reduce the parasitaemia by more than 50% compared to untreated
controls, using in vitro tests (adapted from Hyde 1989).
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the 1980s (Hudson et al. 1991). Like the antimicro-
bial naphthoquinones, atovaquone was shown to
inhibit the parasite mitochondrial respiratory chain,
speciﬁcally acting at the cytochrome bc1 complex,
and thereby inhibiting transport of electrons in the
parasite mitochondria, without aﬀecting the host
mitochondrial functions at the doses used (Fry
and Pudney, 1992). It was therefore postulated that
mutations within the parasite cytochrome b gene at or
close to the atovaquone/ubiquinone binding site or
the catalytic site would inhibit the action of the drug
(Srivastava et al. 1999). Sequence analysis of the cytb
gene fromP. falciparum clones artiﬁcially selected for
atovaquone-resistance in vitro revealed several mu-
tations that were associated with increased atova-
quone tolerance, including Y268S/C, M133I and
V284K within the catalytic domain of Pfcytb,
and others such as G280D, K272R and P275T
(Srivastava et al. 1999; Korsinczky et al. 2000).
Parasites from patients withMalarone® (atovaquone-
proguanil) treatment failure have mutations at posi-
tion 268 of Pfcytb, resulting in a change of amino acid
from tyrosine to serine, cysteine or asparagine
(Srivastava et al. 1999; Schwobel et al. 2003;
Wichmann et al. 2004a; Sutherland et al. 2008).
Some studies have also reported treatment failures
with Malarone where parasites have no mutations in
Pfcytb, suggesting that other mechanisms of resist-
ance might be involved (Wichmann et al. 2004b).
Chloroquine, p-glycoprotein 1 (Pgh1), and the multi-
drug resistance 1 (Pfmdr 1) gene. Although the
mechanism of action of CQ is thought to be via
inhibition of detoxiﬁcation of the products of haemo-
globin digestion by the parasite (Chou et al. 1980;
Bray et al. 1998), resistant parasites were observed to
have a reduced accumulation of CQ compared to
sensitive (CQS) strains (Geary et al. 1986; Saliba
et al. 1998). CQR (and the associated reduced ac-
cumulation of CQ) could also be reversed (at least
in vitro) using calcium-channel antagonists such as
verapamil (Krogstad et al. 1987;Martin et al. 1987), a
phenomenon also observed in mammalian cancer
cells with a multidrug resistance phenotype (Fojo
et al. 1985), and associated with increased expression
of a membrane protein, p-glycoprotein, an ATP-
dependent drug eﬄux pump (reviewed by Schinkel
and Borst, 1991). Based on these observations,
P. falciparum sequences corresponding to homo-
logues of the mdr transporter genes in mammalian
cells were identiﬁed and investigated for their possi-
ble role in CQ resistance (Foote et al. 1989; Wilson
et al. 1989). Two homologues of mdr were found in
the P. falciparum genome, and these were denoted
Pfmdr1 and Pfmdr2 (Wilson et al. 1989). Pfmdr1
encodes a*160 kD protein, termed Pgh 1 (P-glyco-
protein homologue 1), which localizes to the parasite
food vacuole, where it was postulated to regulate
intracellular drug concentrations (Cowman and
Karcz, 1991). Sequence polymorphisms in Pfmdr1
have been correlated with chloroquine-resistant
phenotypes in vitro. One polymorphism, at codon
86, involves a single amino acid change, N86Y. Other
mutations lead to four amino acid changes at codons
Y184F, S1034C, N1042D and D1246Y (Foote et al.
1990b). Analysis of these polymorphisms in a double-
blind study correctly predicted the CQ resistance
proﬁle of 34 of 36 isolates (Foote et al. 1990b).
Molecular epidemiological analyses of ﬁeld isolates
have demonstrated association of some of these poly-
morphisms with CQ resistance in studies from
sub-Saharan Africa (Basco et al. 1995) and Asia
(Cox-Singh et al. 1995; Duraisingh et al. 2000).
Other studies have, however, failed to ﬁnd an asso-
ciation with these allelic variations (Awad-el-Kariem
et al. 1992; Povoa et al. 1998; Mungthin et al. 1999),
including linkage analysis studies (see later). When
ﬁeld isolates are analysed, both mutation and am-
pliﬁcation of the Pfmdr1 gene are found to be wide-
spread in numerous geographical areas (Basco et al.
1995; Price et al. 1999). Together these data suggest
that while Pfmdr1 can modulate P. falciparum para-
site response to CQ, there appears to be no evidence
to date to implicate Pfmdr2.
Discovery of drug resistance markers through linkage
analysis
Linkage analysis is a statistical methodology used to
identify regions of a genome that change a speciﬁc
phenotype of interest. Linkage studies require
analysis of progeny from an experimental genetic
cross between two parasites with diﬀering pheno-
types (in this case drug response), and a detailed gen-
etic map of those progeny, identifying the genomic
regions inherited from each parent (reviewed by
Ranford-Cartwright and Mwangi, 2012). There are
two types of linkage analyses; simple linkage and the
more complicated quantitative trait locus (QTL)
analyses. Simple linkage analysis of Plasmodium gen-
etic crosses is applied where the phenotype segregates
as a bimodal distribution in the progeny (Fig. 2),
which is most simply explained because it is con-
trolled by a single gene. Because the malaria parasite
is haploid for most of its lifecycle, progeny clones
inherit a particular gene from one or the other of the
two parents, and thus also inherit the parental version
of the phenotype controlled by that gene (there can be
no heterozygotes). QTL analysis on the other hand
is applied where the phenotype segregates as a
continuous (unimodal) distribution (Fig. 3), which
suggests that the trait is under the control of multiple
genes, and can be inherited independently from
either parent. Linkage mapping in Plasmodium ex-
ploits the haploid nature of the genome, and also the
high recombination rates obtained in P. falciparum,
which means that candidate genomic regions can be
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mapped to short stretches of DNA and with high
precision (Su et al. 1997, 1999). Amajor advantage of
linkage analysis is that it requires no a priori knowl-
edge of themechanism of action of the drug and/or its
target.
Drug response, like most other cellular chemical
responses, occurs within a network of linear and,
sometimes, intricate web of non-linear pathways and
so linkage analyses might identify not only the
speciﬁc gene targets of the drug but also the biological
processes in which the gene functions (Sen and
Ferdig, 2003). Both simple linkage and QTL
analyses have been successfully employed to charac-
terize genes that control various drug responses in
malaria parasites, two of which will be described
here. Simple linkage analysis was used to identify the
locus responsible for the CQ response (Wellems et al.
1990) and QTL has been used to map the loci linked
to quinine responses (Ferdig et al. 2004).
Chloroquine resistance and the chloroquine resistance
transporter gene (Pfcrt). In an attempt to establish
the genetic basis of CQ resistance, an experimental
cross between a chloroquine-sensitive Central
American clone (HB3) and a multi-drug resistant
Southeast Asian clone (Dd2) was performed
(Wellems et al. 1990). The resulting progeny were
phenotyped for their response to CQ in vitro, and
the phenotype was found to segregate into roughly
two groups: CQ-sensitive and CQ-resistant clones
(Fig. 2). The progeny clones were genotyped at ap-
proximately 900 microsatellite markers across the
14 chromosomes to generate a genetic map. Using
simple linkage analysis, CQR was mapped as a
Mendelian trait to a 400 kb locus on chromosome 7
(Wellems et al. 1991). Further analysis narrowed the
locus to a 36 kb segment with ten open reading frames
(Su et al. 1997), and the speciﬁc locus responsible,
named Pfcrt, was identiﬁed using forward genetics
Fig. 2. The distribution of chloroquine drug response of 35 progeny clones from the HB3×Dd2 cross, shown as the
IC50 levels (concentration of drug required to reduce parasitaemia by 50% compared to untreated controls). The bimodal
shape is indicative that CQ response is controlled by a single gene. Redrawn from data presented in Sen and Ferdig
(2003).
Fig. 3. The distribution of quinine drug response of 35 progeny clones from the HB3×Dd2 cross, shown as the IC50
levels (concentration of drug required to reduce parasitaemia by 50% compared to untreated controls). The unimodal
distribution is indicative of a quantitative multigenic trait. Redrawn from data presented in Sen and Ferdig (2003).
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approaches including allelic exchange (Fidock et al.
2000; Sidhu et al. 2002). Coexpression of mutant
forms of Pfcrt in the presence of a wild-type back-
ground conferred only a modest degree of resistance
to CQS parasites (Fidock et al. 2000), whereas re-
placing the entire Pfcrt allele in a CQS parasite with
alleles of mutant sequences resulted in recombinant
clones with all the hallmarks of a bona ﬁde CQ resis-
tance phenotype. These include increased CQ IC50
values (exceeding 100 nM), acquisition of verapamil
reversibility, and decreased CQ accumulation (Sidhu
et al. 2002).
Pfcrt is a highly fragmented gene with 13 exons,
spanning 3·1 kb, and encodes a 424 amino acid
protein with 10 predicted transmembrane domains
(Fidock et al. 2000). The protein was later localized to
the digestive vacuole membrane by immunoﬂuo-
rescence (Fidock et al. 2000; Cooper et al. 2002).
Mutations in the Pfcrt gene correlate strongly with
in vitro CQ resistance in culture-adapted isolates
from around the world (Fidock et al. 2000; Wootton
et al. 2002). The critical mutation in CQR isolates
results in a change of lysine to threonine at codon 76
(K76T). Other amino acid changes exist in ﬂanking
regions (72–75), with the allele present dependent on
the geographical origin of the isolate. These ad-
ditional mutations, predicted to lie within the trans-
membrane segments, may serve to compensate for a
loss of the endogenous function associated with the
K76T variation, although somemay confer resistance
to related antimalarial agents (Wellems and Plowe,
2001; Chen et al. 2003; Lim et al. 2003; Cooper et al.
2005).
Mutations in Pfcrt are believed to confer CQ resis-
tance by reducing the amount of drug that accumu-
lates within the parasite digestive vacuole (Saliba
et al. 1998). There are several hypotheses to explain
how Pfcrt might exert this eﬀect on digestive vacuole
CQ concentration, either as a consequence of altera-
tions in the pH of the (Bennett et al. 2004), or a direct
eﬀect through enhanced transport of CQ out of the
digestive vacuole (Saliba et al. 1998; Sanchez et al.
2003).
The debate on the mechanism of action of CQ and
how resistance arises is still ongoing. Nevertheless, a
combination of Pfcrt and Pfmdr1 polymorphisms
together has been shown to result in higher levels of
CQR (Babiker et al. 2001). This observation is also
supported by a whole genome survey using micro-
satellite markers to detect linkage disequilibrium
(LD) in a range of parasites, which indentiﬁed the
major locus for CQR at Pfcrt (Fidock et al. 2000;
Djimde et al. 2001), but also an important secondary
locus of Pfmdr 1 on chromosome 5 (Wootton et al.
2002).
Quinine resistance and the Na+/H+ exchanger
(Pfnhe). Quinine is currently reserved for the treat-
ment of severe andmultidrug-resistant malaria, often
in combination with antibiotics for the latter infec-
tions (World Health Organization, 2010). The
molecular mechanism of quinine action against
P. falciparum is not fully understood, although like
CQ it has been shown to accumulate in the parasite’s
digestive vacuole and inhibit haeme detoxiﬁcation
(Jarcho and Torti, 1993). Quinine resistance is not
currently very widespread, which is thought to be a
result of the drug’s short half-life (8 h) and, more
importantly, that multiple genes mediate this trait
(Sen and Ferdig, 2003).
Analysis of progeny from an experimental genetic
cross using the clones Dd2×HB3, which have a
small diﬀerence in quinine IC50 values, revealed a
continuum of drug responses (Fig. 3), implying that
quinine resistance is a multigenic trait (Ferdig et al.
2004). QTL mapping revealed contributory loci on
ﬁve chromosomes, including regions containing
Pfmdr1 and Pfcrt on chromosomes 5 and 7, respect-
ively. This was no surprise since both Pfcrt and
Pfmdr1 inﬂuence quinine response in previous
studies (Cooper et al. 2002; Sidhu et al. 2002). An
additional major locus on chromosome 13, spanning
380 kb and containing about 100 genes, was mapped
as being associated with low level quinine resistance
(Ferdig et al. 2004). One of the candidate genes in this
region, denoted Pfnhe, encodes a sodium-hydrogen
exchanger (NHE) which localizes to the parasitic
plasma membrane (Ferdig et al. 2004). It has been
suggested PFNHE is a proton pump that maintains
parasite pH at 7·4, countering the eﬀects of acidifying
eﬀects of anaerobic glycolysis (Bosia et al. 1993;
Urscher et al. 2011).
Polymorphic regions of Pfnhe were shown to be
associated with low quinine response in a variety of
P. falciparum isolates, with variation in a micro-
satellite repeat denoted ms4670 signiﬁcantly associ-
ated with decreased quinine response in some ﬁeld
isolates (Henry et al. 2009; Okombo et al. 2010), but
not in others (Briolant et al. 2011). These results
suggest that Pfnhe is acting in concert with another
gene, or that quinine resistance is conferred by
another gene located closely to Pfnhe.
Linkage analysis has proved to be a powerful tool
for mapping genomic loci associated with various
phenotypes. However, it relies on the successful
genetic crossing between two parasites with varying
measures of the trait, resulting in progeny that have
unique combinations of alleles. Due to the lack of an
eﬃcient in vitro culture system for the hepatic stages
of P. falciparum, genetic crosses rely on the use of a
suitable mammalian host (a chimpanzee), which is
expensive and ethically problematic. To date only
three genetic crosses of P. falciparum have been suc-
cessfully performed (see Ranford-Cartwright and
Mwangi (2012) for a review on P. falciparum genetic
crosses) which means there is a limited amount of
resources that can be used for further linkage analysis
of drug resistance. At the time of writing this review
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two more crosses are being undertaken: a fourth
P. falciparum cross and the ﬁrst experimental
P. vivax cross (Wellems et al. unpublished).
Discovery of drug resistance markers through GWAS
GWAS use statistical analyses to look for associations
between genetic markers across whole genomes, and
phenotypic traits in parasite samples from natural
populations. The rationale for the use of GWAS to
identify drug resistance loci is that drug resistance
involves signiﬁcant contributions from individual
genes and, due to strong selection, causative alleles
will be found at high frequencies in treated popu-
lations (Nash et al. 2005). In order to carry out
GWAS, one needs to have parasite samples from
natural infections with varying drug responses, as
well as detailed genotypes, usually consisting of
single nucleotide polymorphisms (SNPs). Drug-
resistance in malaria is often due to speciﬁc inherited
mutations that can spread rapidly under drug pres-
sure, leaving signatures of selection in the genome
(selection valleys), because there is not enough time
for the breakdown of linkage between the causal
alleles and ﬂanking regions of the genome (Su et al.
2007). GWAS analysis exploits the presence of such
signatures of selection by scanning for regions of high
LD to map markers that are involved in drug resis-
tance. The ﬁrst proof-of-principle GWAS study
successfully mapped Pfcrt on chromosome 7 using
92 parasites from global locations and just 342
microsatellite markers (Wootton et al. 2002). Here
we discuss the novel markers of antimalarial drug
resistance that have been identiﬁed exclusively
through GWAS analyses.
Halofantrine, meﬂoquine and lumefantrine resistance
and Pf10_0335. Halofantrine is an aryl methanol,
with structural similarity to quinine and other
quinolines, which was introduced as an antimalarial
in 1988. It is thought to inhibit the haeme detoxiﬁca-
tion pathway as it has been shown to form complexes
with ferriprotoporphyrin IX (Dorn et al. 1998). It
was shown to be eﬀective even against multidrug-
resistant malaria (Bloland, 2001). However, its use
as monotherapy has been curtailed by widespread
reports of potential cardiotoxicity (reviewed in
Bouchaud et al. (2009)), although it is used in low
doses as combination therapy with artesunate
(Olliaro and Wells, 2009).
Using 17000 SNPs and in vitro responses to
various antimalarials, VanTyne et al. (2011) analysed
a set of globally-diverse parasites and identiﬁed a
highly polymorphic locus,PF10_0355 (subsequently
renamed as PF3D7_1034500), associated with
halofantrine resistance. Expression of the allele
from a resistant parasite in a sensitive recipient, or
over-expression of the allele from a drug-sensitive
parasite, conferred decreased susceptibility to halo-
fantrine and to other structurally related amino-
quinolines like meﬂoquine and lumefantrine, but not
to the unrelated antimalarials CQ, artemisinin and
atovaquone. It was concluded that increased copy
number of PF10_0355 in the drug-resistant parasites
decreased susceptibility to halofantrine, meﬂoquine
and lumefantrine, although the mechanism is un-
known (Van Tyne et al. 2011).
Artemisinin response and a chromosome 13 locus. The
global roll-out of artemisinin-combination therapy
(ACT) with integrated vector control measures has
contributed to the recent reduction in malaria mor-
bidity and mortality. The mechanism of action
of artemisinin is thought to be either oxidative
damage to parasite membranes or inactivation of
parasite proteins by free radicals produced by the
drug (Hartwig et al. 2009). The endoperoxide moiety
seems to be critical in the function of artemisinins,
and it is believed to produce the active compound
upon interaction with intracellular iron, probably
arising from the haeme degradation by the parasite
(Klonis et al. 2011).
The useful therapeutic life of artemisinin is now
threatened, with recent reports of the emergence of
resistant parasites in Southeast Asia at the Thailand/
Cambodia border (Dondorp et al. 2009). Although it
is not yet known whether these observations are of
‘true’ resistance, parasites exhibit slower clearance
rates following artemisinin treatment compared to
sensitive ones. In a recent study, Cheeseman et al.
(2012) used the diﬀerential clearance rates of parasites
from patients treated with ACT, sampled from
Cambodia, Thailand and Laos, to perform a genome-
wide association study. Their work revealed strong
selection on 33 genomic regions, ten of which con-
tained known antimalarial resistance genes. A 105 kb
locus on chromosome 13 was signiﬁcantly associated
with parasite clearance time in all three parasite
populations, and allelic variation was lowest in
Cambodia (slowest parasite clearance time) compared
to the high diversity observed in parasites from Laos
whose clearance times were shorter, supporting the
hypothesis of a recent selective sweep. Fine mapping
narrowed the locus to a 35 kb region containing seven
candidate genes; this region was estimated to explain
at least 35·2% of the variation observed in clearance
rates of the parasites in this region (Cheeseman et al.
2012), but further forward genetic support will rely
on the development of laboratory assays that can
serve as a surrogate measure of the clearance rate
phenotype in vitro.
While GWAS is gaining popularity after the recent
development ofmore sensitive and robust sequencing
methods, resulting in better marker coverage of the
whole genome, there are still challenges when using
the technique in natural malaria parasite populations.
GWAS methods require homogeneous samples
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i.e. single genotype infections, but malaria parasite
infections in endemic areas are usually composed of
more than one parasite genotype (Conway et al.
1991), necessitating screening and identiﬁcation of
single genotype infections for the analysis. This re-
duces the sample size and thus the power available for
analyses. In addition, parasite population demo-
graphics, including sub-structuring, can inﬂate
associations of phenotypes and loci through false
positives. This problem can be overcome, to an
extent, by using more powerful analytical tools to
overcome data stratiﬁcation, e.g. haplotype likelihood
ratio (HLR), cross population extended haplotype
heterozygosity (XP-EHH), and the mixed model
analysis such as the one successfully used by Van
Tyne et al. to map the locus for halofantrine resis-
tance discussed above (Van Tyne et al. 2011).
Even the strongest statistical association of genetic
linkage does not imply biological causation. This
means that all candidate genes identiﬁed by GWAS
or linkage analyses methods have to be validated and
functionally tested in order to prove their causal pro-
cess with the phenotype under study. This work has
to be done using appropriate laboratory assays.
However, not all phenotypes have appropriate labor-
atory assays which can be used to validate the genes
linked to them. For instance, the variable clearance
time phenotype observed with artemisinin for which
Cheeseman and colleagues identiﬁed candidate loci
does not currently have a suitable laboratory assay to
validate the genes identiﬁed (Cheeseman et al. 2012).
For those phenotypes with suitable laboratory assays
there is a second challenge; the process of functional
validation in P. falciparum can be time consuming
and still has very low success rates (reviewed by
Crabb et al. 2004). Ideally, to prove functional
association between a gene and a phenotype, in this
case drug resistance, the allele of the candidate gene in
a sensitive parasite should be replaced by that from a
resistant parasite (conferring resistance in an appro-
priate assay), and vice versa. In cases where the
candidate loci contain multiple genes, or where the
inheritance of the phenotype is complex, such proof
will be diﬃcult to obtain.
USES OF MOLECULAR MARKERS FOR
ANTIMALARIAL DRUG RESISTANCE
Molecular markers for antimalarial drug resistance
have been used to track the spread of resistant alleles
in patient samples during the time that the drug is in
use. This methodology complements the more lab-
orious and expensive in vitro and in vivo drug eﬃcacy
screening to monitor drug resistance (World Health
Organization, 1990, 2003). The tracking of drug-
resistant alleles has enabled policy makers to prepare
for ﬁrst-line antimalarial changes before in vivo
treatment failures have reached critical levels. A
good example was during the transition from
sulphadoxine/pyrimethamine (SP) to ACTs in most
African countries, where molecular markers for SP
failure were used to anticipate and track treatment
failure, thus enabling a timely switch of the treatment
regimen (Plowe et al. 1997; Kublin et al. 1998; Nzila-
Mounda et al. 1998). It also allows researchers to
monitor the levels of resistance (through prevalence
of drug resistance mutations) when a particular drug
has been withdrawn due to high resistance, when it
would be unethical to conduct eﬃcacy trials (Plowe
et al. 2004).
Molecular markers have also been used retro-
spectively to analyse and understand the factors that
favour the emergence and spread of drug resistance,
including extent of drug use, transmission intensity
and parasite inbreeding rates, by measuring allele
frequencies in archived samples which would not
otherwise have been typed for drug resistance
(Wootton et al. 2002; Roper et al. 2003; Hastings,
2004; Anderson and Roper, 2005). In low trans-
mission areas, where people have low levels of ac-
quired immunity to malaria, and most infections are
symptomatic, themajority ofmalaria episodes receive
treatment. This results in a strong selective advantage
for parasites carrying drug-resistant mutations. This
means that parasite populations are under higher
drug pressure in low transmission areas and so
resistancemutations aremore likely to evolve, survive
and spread in such areas (Hastings, 2004). The sel-
ective advantage is lower in high transmission zones
where infections are more likely to be asymptomatic
and thus remain untreated (Bottius et al. 1996). This
might partly explain why the hotspots for malaria
drug resistance are the lower-transmission regions of
Southeast Asia, especially the countries of Thailand,
Cambodia and Vietnam (Wootton et al. 2002;
Anderson and Roper, 2005; Dondorp et al. 2009;
Cheeseman et al. 2012), although the previous and
heavy use of artemisinin monotherapy (rather than
ACT) has been suggested as an important contribu-
tory factor in the emergence of ART resistance in
Cambodia (Dondorp et al. 2004). Low transmission
regions generally have a lower likelihood of mixed
genotype infections, and thus a higher rate of in-
breeding. Parasite inbreeding has been proposed to
favour the spread of multigenic drug resistance, by
preventing the breakdown and dilution of drug-
resistant haplotypes that occur through genetic
recombination (Schmidt, 1995). Multidrug resist-
ance genotypes are, however, more likely to be
generated when transmission intensities, and the
rate of multiple clone infections, are higher (Curtis
and Otoo, 1986).
In conclusion, diﬀerent genetic and genomic
methodologies have been utilized to reveal the
molecular bases of drug resistance in P. falciparum.
The choice of approach mainly depends on the
existing knowledge of the target of action of the
drugs and the resources available. The development
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of better, faster and inexpensive tools, such as the
recent advances in sequencing whole genomes, will
obviously simplify and improve the accuracy of
locating parasite genomic regions that modulate
drug responses. The development of better methods
for functional analysis, to validate the candidate
genes, will help to elucidate the targets of drug action,
and the mechanism of resistance, knowledge that will
be useful to formulate better drugs for future
deployment.
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